Browsing by Subject "Protease inhibitor"
Now showing items 1-1 of 1
-
(Oxford University Press, 2018)Background. Efavirenz (EFV) and boosted protease inhibitors (bPIs) are still the preferred options for firstline antiretroviral regimens (firstline ART) in Latin America and have comparable short-term efficacy. We assessed ...